-
Brazil suspends Covaxin order over graft allegations
The Covaxin contract to Brazil landed in controversy after the South American country's Attorney General reportedly launched a probe into the deal
-
'Rs150 per Covaxin dose to govt not sustainable in long run'
The Centre's supplying price is pushing the pricing structure for the private sector upward, Bharat Biotech said
-
FDA rejects emergency use authorization for Bharat Biotech’s Covaxin
FDA has asked Ocugen, the US partner of Bharat Biotech to launch an additional trial so that it can file for a full approval
-
'Expect peer review of Covaxin's Phase 3 trials data in Q4'
Suchitra Ella, Joint Managing Director of Bharat Biotech, said Covaxin has reached private hospitals in as many as 28 cities
-
Ocugen pays $15 million upfront to Bharat Biotech for Covaxin rights in Canada
Bharat Biotech and Ocugen Inc have entered into a definitive agreement to co-develop, supply, and commercialise Covaxin for the US market.
-
AIIMS Delhi starts screening of children for Covaxin trials
The trial on children has already started at AIIMS Patna to see if the Bharat Biotech jab is suitable for children.
-
Brazil clears import of Bharat Biotech’s Covaxin, Russia’s Sputnik V
According to Brazillian health regulator Anvisa, Brazil is expected to receive four million doses of Covaxin initially.
-
Covaxin manufacturing to vaccination takes 4 months, says Bharat Biotech
The timeline for manufacturing, testing and release for a batch of Covaxin is approximately 120 days, depending on the technology framework and regula
-
Covid-19 vaccine: ICMR to examine effectiveness of Covishield and Covaxin
The cumulative vaccine doses administered in the country has crossed 20 crore so far
-
Bharat Biotech expects EUA from WHO for Covaxin in July- September
Bharat Biotech said regulatory approvals for Covaxin are in process in more than 60 countries including the USA, Brazil and Hungary among others
